Press Releases
FDA approves GSKs Advil Dual Action with Acetaminophen for over-the-counter use in the United States
GlaxoSmithKline announced that the U.S. FDA has approved Advil Dual Action with Acetaminophen as an over-the-counter (OTC) product for pain relief. The exclusive formula is...
Drug Research
Catalent Announces Supplying Blueprint Medicines Precision Therapy AYVAKIT
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene and cell therapies, and consumer health products, welcomes...
Clinical Trials
Rare Disease Patient Platform Raremark Partners With TriNetX
TriNetX, the global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence (RWE), announced that Raremark, a patient-data...
Press Releases
Signant Health invests for growth with the opening of its new Philadelphia-area office
Signant Health, an industry-leading clinical research technology and solutions company, is proud to announce that it has officially opened a new, leading edge office facility...
Press Releases
Sun Pharma Launches RIOMET ER Oral Suspension in the U.S.
Sun Pharmaceutical Industries Ltd. announced that one of its whollyowned subsidiaries has launched Riomet ER™ in the U.S. as an adjunct to diet and exercise...
Press Releases
Dulaglutide Receives FDA Approval for Reducing MACE in Type 2 Diabetics
The U.S. FDA has approved Trulicity® (dulaglutide) for the reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established...
Clinical Trials
CytoDyn Receives IRB Approval to Initiate Phase 2 Basket Trial for 22 Solid Tumor Cancers
CytoDyn Inc , a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, reported that it has...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.